Putting quality of life back within reach.

(949) 615-7488

Essential Tremor Causes Uncontrollable Shaking, Taking A Significant Toll On Daily Life.

8X

MORE COMMON
THAN PD

ET is 8X more common than PD and effects approximately 10 million people in the United States4.

Significant unmet needs

Essential tremor (ET) is a neurological disorder characterized by uncontrollable and rhythmic shaking or trembling in one or more parts of the body while in use, unlike Parkinson’s disease (PD) where shaking generally occurs during rest1-3.

Tremor in the hands can impair the ability to eat, shave, write, and perform household activities and functions in the workplace. Many people with ET are too embarrassed to go out in public and remain isolated in their homes, which can lead to depression3.

Click for Some References

About Us

Allevion Therapeutics®

Allevion Therapeutics is located in Irvine, California and developing a novel patented smart wrist wearable device to treat hand tremor in patients with movement disorders such as essential tremor. The company has strong intellectual properties in various countries.

Allevx® Smart-Band Technology

Technology allows patients to regain confidence and significantly improves their quality of life.

This breakthrough energy system has the potential to address ET and other movement related disorders such as Parkinson’s disease (PD) and Dystonia.

Non-invasive Energy-based System For Treating Essential Tremor

ALLEVX® Technology

Smart Energy System

Allevx®

  • Non-invasive wrist wearable neuromodulation therapy delivers stimulation to multiple wrist nerves (median, radial, ulnar) with minimal power.
  • Short therapy session (20 minutes) can be completed multiple times without recharging.
  • Real-time tremor assessment & Analysis chart.
  • Fast charging unit.
  • Single device can be used on either or both wrists.
  • No calibration required.
Learn More

The Unmet Needs of Essential Tremor Represent a Significant Market Opportunity.

image

Large US And Global Market Potential

Approx

160MWorldwide Suffer From ET
Upto
50%

Do Not Respond To Rx Therapy

Few effective prescription medications are available for treating ET. Between 30% to 50% of npatients do not respond to either first line pharmacological agents: propanol and primidone.

>6%

Annual Increase In Populations With ET

Due to the aging population, the number of individuals with ET is expected to experience annual double digit growth.

60%

Military Veterans

Patients’ Testimonials

Need Support? Get In Touch!

Learn More About Our Innovative Medical Devices.

Reach out Now